RVLPQ (RVL Pharmaceuticals) Ending Cash Position: $19.16 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RVLPQ RVL Pharmaceuticals PLC RVLPQ
12 GF Score
Price $0.00
View Full Analysis

What is RVL Pharmaceuticals Ending Cash Position?

RVL Pharmaceuticals RVLPQ -90.00% 12 Ending Cash Position is $19.16 Mil as of Jun. 2023. GuruFocus rates RVLPQ with a GF Score™ of 12/100.

RVL Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2023 was $19.16 Mil.

RVL Pharmaceuticals's quarterly Ending Cash Position declined from Dec. 2022 ($44.54 Mil) to Mar. 2023 ($32.64 Mil) and declined from Mar. 2023 ($32.64 Mil) to Jun. 2023 ($19.16 Mil).

RVL Pharmaceuticals's annual Ending Cash Position declined from Dec. 2020 ($114.05 Mil) to Dec. 2021 ($40.44 Mil) but then increased from Dec. 2021 ($40.44 Mil) to Dec. 2022 ($44.54 Mil).

RVL Pharmaceuticals Ending Cash Position Related Terms

RVL Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for RVL Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals Ending Cash Position Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Ending Cash Position
Get a 7-Day Free Trial 70.83 95.87 114.05 40.44 44.54

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.41 59.75 44.54 32.64 19.16
RVLPQ
12GF Score
RVL Pharmaceuticals PLC RVLPQ
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RVL Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

RVL Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=40.444+4.099
=44.54

RVL Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=32.64+-13.481
=19.16

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $19.16 Mil mean?
RVL Pharmaceuticals (RVLPQ) has a Ending Cash Position of $19.16 Mil as of Jun. 2023. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on RVL Pharmaceuticals and its competitors.
Is RVL Pharmaceuticals' Ending Cash Position too high?
RVL Pharmaceuticals' current Ending Cash Position is $19.16 Mil. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RVL Pharmaceuticals' Ending Cash Position compare to SNPX and THAR?
RVL Pharmaceuticals' Ending Cash Position of $19.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on RVL Pharmaceuticals and its competitors. RVL Pharmaceuticals's current Ending Cash Position is $19.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RVL Pharmaceuticals stock overvalued right now?
RVL Pharmaceuticals (RVLPQ) has a current Ending Cash Position of $19.16 Mil. The current Ending Cash Position is $19.16 Mil. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current Ending Cash Position is $19.16 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RVL Pharmaceuticals Business Description

Address 400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
12GF Score

Get the complete analysis for RVLPQ

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price